ImmuPharma (LON:IMM) Stock Price Down 9.9% - Here's What Happened

Key Points

• ImmuPharma's stock price dropped by 9.9% to GBX 10.90 ($0.15) amidst unusually high trading volume of 14,800,078 shares, an increase of 72% compared to the average session.
• The company reported a quarterly EPS of GBX (0.38) and analysts forecast a significantly negative earnings per share of -339.0000022 for the current year.
• ImmuPharma is recognized for its development of peptide-based therapeutics, particularly the lead program, Lupuzor™, aimed at treating autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) was down 9.9% on Wednesday . The company traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). Approximately 14,800,078 shares changed hands during trading, an increase of 72% from the average daily volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Price Performance

The stock has a 50 day simple moving average of GBX 4.84 and a two-hundred day simple moving average of GBX 3.44. The company has a market cap of £54.47 million, a price-to-earnings ratio of -1,224.72 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.